Autoimmune Hepatitis After Liver Transplantation

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 4, 2012, Pages 346-353

  Liberal, Rodrigo ^a,b   Longhi, Maria Serena ^a   Grant, Charlotte R ^a   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b University of Porto   (Portugal)

Author keywords

Autoimmune hepatitis; De novo autoimmune hepatitis; Liver transplantation; Recurrent autoimmune hepatitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; DISEASE COURSE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; RECURRENT DISEASE; REVIEW; SURVIVAL RATE;

HEPATITIS, AUTOIMMUNE; HUMANS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84858706587     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.10.028     Document Type: Review

References (83)

1. Sanchez-Urdazpal L., Czaja A.J., van Hoek B., et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992, 15:215-221.
2. Mottershead M., Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol 2008, 14:3388-3395.
3. Manns M.P., Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
4. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
5. Hubscher S.G. What is the long-term outcome of the liver allograft?. J Hepatol 2011, 55:702-707.
6. Neuberger J., Portmann B., Calne R., et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984, 37:363-365.
7. Vergani D., Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002, 36:271-276.
8. Czaja A.J. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplant 2002, 8:505-513.
9. Sánchez-Fueyo A., Strom T.B. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011, 140:51-64.
10. Kerkar N., Hadzić N., Davies E.T., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
11. Reich D.J., Fiel I., Guarrera J.V., et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000, 32:693-700.
12. Wright H.L., Bou-Abboud C.F., Hassanein T., et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992, 53:136-139.
13. Devlin J., Donaldson P., Portmann B., et al. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transplant Surg 1995, 1:162-165.
14. Birnbaum A.H., Benkov K.J., Pittman N.S., et al. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997, 25:20-25.
15. Prados E., Cuervas-Mons V., de la Mata M., et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998, 66:1645-1650.
16. Ratziu V., Samuel D., Sebagh M., et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999, 30:131-141.
17. Götz G., Neuhaus R., Bechstein W.O., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999, 31:430-431.
18. Milkiewicz P., Hubscher S.G., Skiba G., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999, 68:253-256.
19. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000, 32:185-192.
20. Manns M.P., Bahr M.J. Recurrent autoimmune hepatitis after liver transplantation: when non-self becomes self. Hepatology 2000, 32:868-870.
21. Gonzalez-Koch A., Czaja A.J., Carpenter H.A., et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transplant 2001, 7:302-310.
22. Duclos-Vallée J.C., Sebagh M., Rifai K., et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003, 52:893-897.
23. Vogel A., Heinrich E., Bahr M.J., et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transpl 2004, 18:62-69.
24. Demetris A.J., Adeyi O., Bellamy C.O., et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006, 44:489-501.
25. Kotlyar D.S., Campbell M.S., Reddy K.R. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 2006, 101:1370-1378.
26. Campsen J., Zimmerman M.A., Trotter J.F., et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transplant 2008, 14:1281-1286.
27. Rowe I.A., Webb K., Gunson B.K., et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008, 21:459-465.
28. Schramm C., Bubenheim M., Adam R., et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transplant 2010, 16:461-469.
29. Narumi S., Hakamada K., Sasaki M., et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 1999, 31:1955-1956.
30. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
31. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
32. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
33. Sempoux C., Horsmans Y., Lerut J., et al. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997, 17:311-315.
34. Czaja A.J. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid-dependent after liver transplantation?. Liver Transplant Surg 1999, 5:460-463.
35. Shemesh E., Shneider B.L., Savitzky J.K., et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 2004, 113:825-832.
36. Kerkar N., Annunziato R.A., Foley L., et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006, 43:629-634.
37. Hubscher S.G. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transplant 2001, 7:285-291.
38. Gautam M., Cheruvattath R., Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transplant 2006, 12:1813-1824.
39. Renz J.F., Ascher N.L. Liver transplantation for nonviral, nonmalignant diseases: problem of recurrence. World J Surg 2002, 26:247-256.
40. Hurtova M., Duclos-Vallee J.C., Johanet C., et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transplant 2001, 7:556-558.
41. Kerkar N., Dugan C., Rumbo C., et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005, 5:1085-1089.
42. Dubel L., Farges O., Johanet C., et al. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998, 65:1072-1075.
43. Salcedo M., Vaquero J., Bañares R., et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002, 35:349-356.
44. Riva S., Sonzogni A., Bravi M., et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transplant 2006, 12:573-577.
45. Mieli-Vergani G., Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004, 40:3-7.
46. Inui A., Sogo T., Komatsu H., et al. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transplant 2005, 11:504-507.
47. Hernandez H.M., Kovarik P., Whitington P.F., et al. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001, 32:131-136.
48. Dubel L., Farges O., Sato Y., et al. Development of anti-tissue antibodies in the rat liver transplant model. Transplantation 1998, 65:1135-1137.
49. Andries S., Casamayou L., Sempoux C., et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001, 72:267-272.
50. Richter A., Grabhorn E., Helmke K., et al. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transpl 2007, 21:427-432.
51. Gupta P., Hart J., Millis J.M., et al. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001, 71:664-668.
52. Spada M., Bertani A., Sonzogni A., et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. Transplant Proc 2001, 33:1747-1748.
53. Miyagawa-Hayashino A., Haga H., Egawa H., et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004, 78:128-135.
54. Venick R.S., McDiarmid S.V., Farmer D.G., et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007, 7:955-963.
55. Heneghan M.A., Portmann B.C., Norris S.M., et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001, 34:464-470.
56. Jones D.E., James O.F., Portmann B., et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999, 30:53-57.
57. Tan C.K., Sian Ho J.M. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transplant 2001, 7:461-465.
58. Berardi S., Lodato F., Gramenzi A., et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?. Gut 2007, 56:237-242.
59. Fiel M.I., Agarwal K., Stanca C., et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transplant 2008, 14:861-871.
60. Lodato F., Azzaroli F., Tamè M.R., et al. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol 2009, 15:5449-5454.
61. Ward S.C., Schiano T.D., Thung S.N., et al. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transplant 2009, 15:1826-1833.
62. Kontorinis N., Agarwal K., Elhajj N., et al. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transplant 2006, 12:827-830.
63. Selzner N., Guindi M., Renner E.L., et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2010, 55:207-217.
64. Albert L.J., Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 1999, 341:2068-2074.
65. Bogdanos D.P., Choudhuri K., Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001, 21:225-232.
66. Sakaguchi S., Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. Rev Immunogenet 2000, 2:147-153.
67. Gao E.K., Lo D., Cheney R., et al. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988, 336:176-179.
68. Bucy R.P., Xu X.Y., Li J., et al. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993, 151:1039-1050.
69. Wu D.Y., Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999, 162:6926-6933.
70. Damoiseaux J.G., van Breda Vriesman P.J. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol (Praha) 1998, 44:1-9.
71. Shi Y.F., Sahai B.M., Green D.R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989, 339:625-626.
72. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
73. Thornton A.M., Donovan E.E., Piccirillo C.A., et al. Cutting edge: IL-2 is critically required for the in vitro activation of CD4(+)CD25(+) T cell suppressor function. J Immunol 2004, 172:6519-6523.
74. Zheng X.X., Kang H.G., Zhang D., et al. Effects of cyclosporine on transplant tolerance: the role of IL-2. Am J Transplant 2007, 7:1907-1916.
75. Hess A.D., Fischer A.C. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989, 48:895-900.
76. Hess A.D., Horwitz L.R., Laulis M.K., et al. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol 1993, 69:341-350.
77. Demirkiran A., Kok A., Kwekkeboom J., et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transplant 2006, 12:277-284.
78. Longhi M.S., Ma Y., Bogdanos D.P., et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
79. Aguilera I., Wichmann I., Sousa J.M., et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001, 126:535-539.
80. Rodriguez-Mahou M., Salcedo M., Fernandez-Cruz E., et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007, 83:1126-1129.
81. Salcedo M., Rodriguez-Mahou M., Rodriguez-Sainz C., et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transplant 2009, 15:530-539.
82. Yoshizawa K., Shirakawa H., Ichijo T., et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transpl 2008, 22:385-390.
83. Grammatikopoulos T., Mytilinaiou M.G., Bogdanos D.P., et al. Glutathionine S-transferase theta 1 (Gstt1) mismatch does not account for post liver transplant de novo autoimmune hepatitis. Hepatology 2009, 50:635a-636a.